Hexarelin
Overview
A potent synthetic ghrelin-receptor agonist with documented cardioprotective signaling in preclinical models, mediated in part through CD36 in cardiac tissue independent of GH release.
Research profile · for clinicians
Based on research: a potent GH-releasing peptide with a distinctive cardiac profile. Beyond GH release, preclinical ischemia-reperfusion models examine CD36-mediated cardioprotective signaling in cardiomyocytes — the basis for its cardiovascular-research references.
Mechanism of action
Strong GHS-R1a agonism produces robust GH pulses; concurrent CD36 binding in cardiomyocytes has been linked to cardioprotective effects in rodent ischemia-reperfusion models.
Research record
- [01]Comparative GH-release studies vs. GHRP-6 and ipamorelin.
- [02]Preclinical cardioprotection in ischemia-reperfusion models.
Selected references
Hexarelin and the cardiovascular system
Cardiovasc. Res., 2007